Sunstone participates in EUR 39m financing round of Targed Biopharma

An investor syndicate including venture capital firm Sunstone Life Science Ventures and Norwegian Hadean ventures has injected EUR 39m into Dutch biotech company Targed Biopharmaceuticals, which develops treatments for blood-clotting disorders.
Jacob L. Moresco, investment director at Sunstone Life Science Ventures | Photo: Sunstone Life Science Ventures
Jacob L. Moresco, investment director at Sunstone Life Science Ventures | Photo: Sunstone Life Science Ventures
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen

Dutch biotech company Targed Biopharmaceuticals has evidently drawn attention to its treatment approach for blood-clotting disorders, also known as thrombotic diseases, as an investor syndicate has just injected EUR 39m into the company.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading